DOVATO 50 mg/300 mg, film-coated tablet 30 tablets, CIP 3400930182550
Active ingredients: Dolutegravir, Dolutegravir sodium, Lamivudine
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tablets, CIP 3400930182550orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DOVATO 50 mg/300 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 1 flacon polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant polypropylène de 30 comprimés
- Marketing authorisation holder
- VIIV HEALTHCARE (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- SIDA (de type VIH1), dans le cadre de certains critères précisément définis ; JOURNAL OFFICIEL ; 12/03/20
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 13 Mar 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67301231CIP73018255CIP133400930182550Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LAMIVUDINEcomprimé | 300 mg · un comprimé | SA |
| DOLUTÉGRAVIR SODIQUEcomprimé | — | SA |
| DOLUTÉGRAVIRcomprimé | 50 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.